A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma

PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

December 31, 2016

Conditions

Chronic Hepatitis C Infection

Interventions

DRUG

ombitasvir/paritaprevir/ritonavir and dasabuvir

Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

DRUG

ombitasvir/paritaprevir/ritonavir

Tablet; ombitasvir coformulated with paritaprevir and ritonavir

DRUG

ribavirin

Tablet